Table 1.
Non-randomized single agent docetaxel studies in pretreated esophagogastric cancer.
| Docetaxel schedule | Previous treatment | Study population (patient numbers) | ORR | TTP | OS | Reference |
|---|---|---|---|---|---|---|
| Docetaxel 75 mg/m2 day 1 q3w | ? (4 had paclitaxel based regimens) | EAC, EGJAC (11) | 0% | 1.4 months | 4 months | Heath et al. [2002] |
| Docetaxel 70 mg/m2 day 1 q3w | Cisplatin / Nedaplatin ± 5FU ± RT | SEC (46), EAC (3) | 16% | 8.1 months | Muro et al. [2004] | |
| Docetaxel 36 mg/m2 days 1 + 8 + 15 + 22 + 29 + 36 q8w | Cisplatin + 5FU (12) or PELF (9) | GAC (21) | 5% | 3.5 months | Graziano et al. [2000] | |
| Docetaxel 100 mg/m2 day 1 q3w | ECF or PELF | GAC (30) | 17% | 6 months | Guiliani et al. [2003] | |
| Docetaxel 75 mg/m2 day 1 q3w | Cisplatin + 5FU | GAC (49) | 16% | 2.5 months | 8.3 months | Lee et al. [2008] |
| Docetaxel 35–50 mg/m2 day 1 q2w | S-1 ± Cisplatin | GAC (15) | 8% | Kimura et al. [2011] |
5FU, 5-fluorouracil; EAC, esophageal adenocarcinoma; ECF, epirubicin, cisplatin, 5FU; EGJAC, esophagogastric junction adenocarcinoma; GAC, gastric adenocarcinoma; ORR, overall response rate; OS, overall survival; q3w, every 3 weeks; q8w, every 8 weeks; PELF, cisplatin, epirubicin, leucovorin, 5FU; RT, radiotherapy; SEC, squamous esophageal cancer; TTP, time-to-progression.